Jinyu Bio-Technology to repurchase, cancel employee stock plan shares

Jinyu Bio-Technology's third-quarter report for 2025 indicates a robust financial performance, with operating income reaching CNY 1.04 bn and a net profit attributable to shareholders of CNY 161.3m for the first nine months. The company's total assets stood at CNY 6.73 bn as of September 30, 2025.

Concurrently, Jinyu Bio-Technology announced a proposed repurchase and cancellation of 120,000 shares from its 2023 employee stock ownership plan at CNY 6.23 per share. This action follows the departure of five participants whose unvested equity portions are no longer eligible. The company confirmed this will not materially impact its operations or financial standing.

Following the share repurchase and cancellation, the company's total shares will decrease from 1,111,747,826 to 1,111,197,326, with a corresponding reduction in registered capital. This move is consistent with previous board and shareholder approvals regarding the employee stock plan adjustments.